Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

HF 3234

as introduced - 82nd Legislature (2001 - 2002) Posted on 12/15/2009 12:00am

KEY: stricken = removed, old language.
underscored = added, new language.

Bill Text Versions

Engrossments
Introduction Posted on 02/11/2002

Current Version - as introduced

  1.1                          A bill for an act 
  1.2             relating to health; requiring health insurance 
  1.3             coverage for surveillance testing for ovarian cancer; 
  1.4             amending Minnesota Statutes 2000, section 62A.30, 
  1.5             subdivision 2, by adding a subdivision. 
  1.6   BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA: 
  1.7      Section 1.  Minnesota Statutes 2000, section 62A.30, 
  1.8   subdivision 2, is amended to read: 
  1.9      Subd. 2.  [REQUIRED COVERAGE.] Every policy, plan, 
  1.10  certificate, or contract referred to in subdivision 1 issued or 
  1.11  renewed after August 1, 1988, that provides coverage to a 
  1.12  Minnesota resident must provide coverage for routine screening 
  1.13  procedures for cancer, including mammograms, surveillance tests 
  1.14  for ovarian cancer for women who are at risk for ovarian cancer 
  1.15  as defined in subdivision 3, and pap smears, when ordered or 
  1.16  provided by a physician in accordance with the standard practice 
  1.17  of medicine. 
  1.18     Sec. 2.  Minnesota Statutes 2000, section 62A.30, is 
  1.19  amended by adding a subdivision to read: 
  1.20     Subd. 3.  [OVARIAN CANCER SURVEILLANCE TESTS.] For purposes 
  1.21  of subdivision 2: 
  1.22     (a) "At risk for ovarian cancer" means: 
  1.23     (1) having a family history: 
  1.24     (i) with one or more first or second-degree relatives with 
  1.25  ovarian cancer; 
  2.1      (ii) of clusters of women relatives with breast cancer; or 
  2.2      (iii) of nonpolyposis colorectal cancer; or 
  2.3      (2) testing positive for BRCA1 or BRCA2 mutations. 
  2.4      (b) "Surveillance tests for ovarian cancer" means annual 
  2.5   screening using: 
  2.6      (1) CA-125 serum tumor marker testing; 
  2.7      (2) transvaginal ultrasound; and 
  2.8      (3) pelvic examination.  
  2.9      Sec. 3.  [EFFECTIVE DATE.] 
  2.10     Sections 1 and 2 are effective August 1, 2002, and apply to 
  2.11  coverage issued or renewed on or after that date.